

REFERENCES

AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2019;139(25):e1082-e1143.

Amgen. Olpasiran trials of cardiovascular events and lipoprotein(a) reduction (OCEAN(a)) - outcomes trial. Updated December 18, 2023. <u>https://clinicaltrials.gov/study/NCT05581303</u>

Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet.* 2010;376(9753):1670-1681.

Berg K. A new serum type system in man—The Lp system. Acta Pathol Microbiol Scand A. 1963;59(3):369-382.

Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med.* 2015;372(25):2387-2397.

Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet.* 2012;380(9841):581-590.

Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC Health Promotion Series. *J Am Coll Cardiol*. 201872(10):1141-1156.

Goldstein Joseph L, Brown Michael S. A century of cholesterol and coronaries: From plaques to genes to statins. *Cell.* 2015;161(1):161-172.

Hajar R. Risk factors for coronary artery disease: Historical perspectives. *Heart Views.* 2017;18(3):109-114.

Khullar D, Bond AM, O'Donnell EM, Qian Y, Gans DN, Casalino LP. Time and financial costs for physician practices to participate in the Medicare Merit-based Incentive Payment System: A qualitative study. *JAMA Health Forum*. 2021;2(5):e210527.

Knowles JW, Howard WB, Karayan L, et al. Access to nonstatin lipid-lowering therapies in patients at high risk of atherosclerotic cardiovascular disease. *Circulation.* 2017;135(22):2204-2206.

Kronenberg F, Mora S, Stroes, ES et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. *Eur Heart J.* 2022; 43(39):3925-3946.

Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. *J Am Coll Cardiol.* 2022;80(14):1366-1418.


Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). *Eur Heart J.* 2020;41(1):111-188.

Myers KD, Farboodi N, Mwamburi M, et al. Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes. *Circ Cardiovasc Qual Outcomes.* 2019;12(8):e005404.

National Lipid Association. Access to therapy. Published 2020. Accessed December 1, 2023. https://www.lipid.org/access_to_therapy

Navar AM, Taylor B, Mulder H, et al. Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy. *JAMA Cardiol.* 2017;2(11):1217-1225.

Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med*. 2023;388:1353-1364.



Novartis Pharmaceuticals. Assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with CVD (Lp(a)HORIZON). Updated November 14, 2023. <u>https://clinicaltrials.gov/study/NCT04023552</u>

Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Diseases in Adults. *Can J Cardiol*. 2021;37(8):1129-1150.

Prime Education L. Nonstatin Prior Authorization Checklist. Published 2021. Accessed December 9, 2023. https://pcna.net/wp-content/uploads/2022/03/Nonstatin-Prior-AuthorizationChecklist_2.pdf

Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. *N Engl J Med.* 2019;380(11):1022-1032.

Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. *N Engl J Med.* 2020;382(16):1507-1519.

Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a Scientific Statement From the American Heart Association. *Arterioscler Thromb Vasc Biol.* 2022;42: e48-e60.

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med.* 2017;376(18):1713-1722.

Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med.* 2018;379(22):2097-2107.

Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. *Circulation.* 2022;145(8):e153-e639.

Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in Clinical Practice: A Biomarker Whose Time Has Come. A Scientific Statement from the National Lipid Association. *J Clin Lipidol.* 2022;16(5):e77-e95.